Billions of dollars are at stake, so the fight over who owns CRISPR is back in court
Posted by btwatson on April 30, 2018 8:35 pm
Tags:
Categories:
Uncategorized
Source: Billions of dollars are at stake, so the fight over who owns CRISPR is back in court

Credit for a game-changing breakthrough in biotechnology, a potential Nobel Prize, and oh yes, gobs of money have proved motive enough for the University of California, Berkeley, to keep up its all-but-lost dispute with the Broad Institute of MIT and Harvard over who owns the rights to the gene-editing tool CRISPR. The two parties squared off again today in a federal court in Washington, DC.
Background: The Berkeley team and its collaborators first filed a patent application in May 2012 to use CRISPR in any kind of cell. In December of that year, Broad researchers filed an application but paid an extra fee for an expedited route to patent CRISPR in eukaryotic cells—those in plants, animals, and people. The Broad was granted several patents.
Patent fight: Berkeley challenged that decision, asking the US Patent & Trademark Office to reconsider. In a ruling last year, the office’s patent trial and appeal board decided in favor of the Broad, saying the two teams’ discoveries didn’t overlap and that the Broad’s patents were, in fact, valid.
Appeal: The University of California appealed that decision, and today it tried to convince federal judges in DC that the patent board made legal errors when it issued its ruling. The judges didn’t seem swayed—but they won’t issue a written decision until later this year at the earliest.
CRISPR’s future: At stake is likely to be billions of dollars in licensing agreements. If the Broad ultimately prevails, companies currently licensing technology from the University of California—like CRISPR Therapeutics and Intellia Therapeutics—will instead need to seek approval from the Broad Institute for rights to use CRISPR. That could send their stock tumbling and potentially delay their plans to begin clinical trials using the gene-editing technology.
Image credit:
- Emily Caulfield
Published at Mon, 30 Apr 2018 19:27:01 +0000
Crispr News
-
Gene Editing Tools Market Size And Forecast | Thermofisher Scientific, CRISPR Therapeutics, Editas Medicine, NHGRI, Intellia Therapeutics, Merck KGaA, Horizo€‹€‹n – The Daily Vale - The Daily ValeMay 25, 2022
-
Breakthrough CRISPR-Combo edits some genes and activates others - New AtlasMay 25, 2022
-
Gene Editing Service Market Increasing Demand and Dynamic Growth with Forecast 2029 | BBI Life Sciences, Bio Basic, CRISPR Therapeutics, Caribou Biosciences, DNA 2.0 (ATUM) – The Daily Vale - The Daily ValeMay 25, 2022
-
UK uses Brexit freedom to speed up the development of 'gene-edited' crops and livestock - Daily MailMay 24, 2022
-
Texas A&M AgriLife researchers use CRISPR technology to modify starches in potatoes - AgriLife TodayMay 24, 2022
-
Clustered Regularly Interspaced Short Palindromic Repeats(CRISPR) Technology Market Size And Forecast | Thermo Fisher Scientific, Merck, GenScript, Integrated DNA Technologies, Horizon Discovery Group, Agilent Technologies, Cellecta, GeneCopoeia, - The Daily ValeMay 24, 2022
-
The Goldman Sachs Group Cuts CRISPR Therapeutics (NASDAQ:CRSP) Price Target to $46.00 - Defense WorldMay 24, 2022
-
Goldman Sachs Maintains Neutral on CRISPR Therapeutics, Lowers Price Target to $46 - Benzinga - BenzingaMay 24, 2022
-
No Sun, No Problem: CRISPR'd Tomatoes Produce Vitamin D - Genetic Engineering & Biotechnology NewsMay 24, 2022
-
Gene Editing Service Market Size 2022 Overview by 2029 | Key Players – BBI Life Sciences, Bio Basic, CRISPR Therapeutics, Caribou Biosciences, DNA 2.0 (ATUM) – The Daily Vale - The Daily ValeMay 24, 2022
-
Instability can benefit teams with different expertise - Verve TimesMay 24, 2022
-
CRISPR Editing Accidentally Turns Hamsters Into Angry Bullies - IFLScienceMay 23, 2022
-
Piper Sandler Maintains Overweight on CRISPR Therapeutics, Lowers Price Target to $115 - Benzinga - BenzingaMay 23, 2022
-
Modified CRISPR tool boosts UBE3A levels in mice - SpectrumMay 20, 2022
-
How tweaking genes keeps corn and rice on your plate - Cold Spring Harbor LaboratoryMay 18, 2022
- CRISPR rivals put patents aside to help in fight against Covid-19 – STAT
- CRISPR 2.0: Base Editing in the Groove – Genetic Engineering & Biotechnology News
- The Promises of CRISPR Genome Editing in Biomedicine – Labiotech.eu
- The Code Breaker and Crispr People — the ethics of editing humanity – Financial Times
- ERS Genomics Licenses CRISPR Patents to CRO ZeClinics – GenomeWeb
- The Dark Side of CRISPR – Scientific American
- ERS Genomics and ZeClinics Sign CRISPR/Cas9 License Agreement – BioSpace
- Scientists Use CRISPR To Create Model of AML Progression – AJMC.com Managed Markets Network
- DECODR app identifies DNA mutations from CRISPR gene therapies – European Pharmaceutical Review
- CRISPR/Cas technology as a promising weapon to combat viral infections – Wiley
- Neanderthal-like ‘mini-brains’ created in lab with CRISPR – Nature.com
- Affordable CRISPR app reveals unintended mutations at site of CRISPR gene repair – Phys.org
- Affordable CRISPR app reveals unintended mutations at site of CRISPR gene repair – EurekAlert
- New CRISPR tech targets human genome’s complex code: Programmable CRISPR/Cas9-based kinase offers insights into, control over regulatory histone proteins – Science Daily
- After ditching Editas, AbbVie taps Caribou for new CRISPR, CAR-T pact – FierceBiotech
Leave a Reply
You must be logged in to post a comment.